Life science startup StemoniX has raised a $2.5 million seed round.

The new funds came from Seed San Diego, Gopher Angels, and Oklahoma Angels, according to StemoniX’s CEO Ping Yeh.

The company, recently graduated from the EvoNexus incubator, manufactures human cells from skin so drugmakers can find out what works early in the process. The idea is that drugs can first be tested for toxicity and efficacy on human cells before advancing to human trials. The company’s products include stem cells, cardiac cells, and brain cells that can also mimic diseases.

The new cash will be used to support customers and growth, Yeh said.